ena-STUDY-UNIVERSITY OF EXETER-29-06-2017-18:58:44:993-513
The impact of NOD2 variants on fecal microbiota in Crohn's disease and healthy controls
Background/AimsCurrent models of Crohn's disease (CD) describe an inappropriate immune response to gut microbiota in genetically susceptible individuals. NOD2 variants are strongly associated with development of CD, and NOD2 is part of the innate immune response to bacteria. This study aimed to identify differences in fecal microbiota in CD patients and healthy controls stratified by NOD2 genotype.MethodsPatients with CD and healthy controls of known NOD2 genotype were identified from patients in UK IBD genetics studies and the Cambridge bioresource (genotyped healthy individuals). Individuals with known CD-associated NOD2 mutations were matched to those with wild-type genotype. We obtained fecal samples from patients in clinical remission with low fecal calprotectin (<250µg/g) and controls without gastrointestinal disease. After extracting DNA, the V1-2 region of 16S rRNA genes were PCR-amplified and sequenced. Analysis was undertaken using the mothur package. Volatile organic compounds (VOC) were also measured.Results94 individuals were in the primary analysis (39 CD, 31 bioresource controls and 24 household controls). Comparing CD with healthy controls, there were reductions in bacterial diversity, Ruminococcaceae, Rikenellaceae and Christensenellaceae and an increase in Enterobacteriaceae. However, no significant differences could be identified in microbiota or VOC by NOD2 genotype either in the CD or healthy control cohorts.ConclusionsIn this well-controlled study of NOD2 genotype and fecal microbiota, we identified no significant genotype-microbiota associations. This suggests that the changes associated with NOD2 genotype might only be seen at the mucosal level, or that environmental factors and prior inflammation are the predominant determinant of the observed dysbiosis in gut microbiota.
Background/AimsCurrent models of Crohn's disease (CD) describe an inappropriate immune response to gut microbiota in genetically susceptible individuals. NOD2 variants are strongly associated with development of CD, and NOD2 is part of the innate immune response to bacteria. This study aimed to identify differences in fecal microbiota in CD patients and healthy controls stratified by NOD2 genotype.MethodsPatients with CD and healthy controls of known NOD2 genotype were identified from patients in UK IBD genetics studies and the Cambridge bioresource (genotyped healthy individuals). Individuals with known CD-associated NOD2 mutations were matched to those with wild-type genotype. We obtained fecal samples from patients in clinical remission with low fecal calprotectin (<250µg/g) and controls without gastrointestinal disease. After extracting DNA, the V1-2 region of 16S rRNA genes were PCR-amplified and sequenced. Analysis was undertaken using the mothur package. Volatile organic compounds (VOC) were also measured.Results94 individuals were in the primary analysis (39 CD, 31 bioresource controls and 24 household controls). Comparing CD with healthy controls, there were reductions in bacterial diversity, Ruminococcaceae, Rikenellaceae and Christensenellaceae and an increase in Enterobacteriaceae. However, no significant differences could be identified in microbiota or VOC by NOD2 genotype either in the CD or healthy control cohorts.ConclusionsIn this well-controlled study of NOD2 genotype and fecal microbiota, we identified no significant genotype-microbiota associations. This suggests that the changes associated with NOD2 genotype might only be seen at the mucosal level, or that environmental factors and prior inflammation are the predominant determinant of the observed dysbiosis in gut microbiota.